CUDC ‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells

Int J Oncol. 2023 Dec;63(6):131. doi: 10.3892/ijo.2023.5579. Epub 2023 Oct 13.ABSTRACTBladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therapeutic agent for bladder cancer using chemosensitivity methods. The results showed that CUDC‑101 induced cytotoxic effects, inhibited growth vitality and proliferation in a dose‑dependent manner. CUDC‑101 also altered the skeletal morphology and microfilament structure, while blocking cell cycle progression and causing apoptosis. These results supported the proposed cytotoxic effects of CUDC‑101, in addition to its inhibitory effects on cell division and proliferation in EGFR‑overexpressing bladder cancer cells. Therefore CUDC‑101 may to be a potential therapeutic option for the treatment of bladder cancer.PMID:37830158 | DOI:10.3892/ijo.2023.5579

Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Zhenxing Wang Lanxin Li Chunhong Chu Xiangkai Wei Qian Liu Rui Wang Guoliang Zhang Guangyao Wu Ying Wang Lei An Xiaodong Li Source Type: research